Related Experiment Video

Updated: May 16, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenomics of chemotherapeutic susceptibility and toxicity

Erika L Moen1, Lucy A Godley2, Wei Zhang3

  • 1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.

Genome Medicine
|December 4, 2012
PubMed

Insights

Personalized medicine uses genetic information to tailor cancer treatments. Pharmacogenomics identifies genetic markers for chemotherapy response and toxicity, but clinical implementation faces challenges.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Genetics

Background:

  • Personalized medicine aims to customize treatments based on individual genetic makeup.
  • Pharmacogenomics investigates how genetic variations influence drug response and toxicity.
  • Oncology is increasingly adopting personalized medicine strategies, particularly pharmacogenomics.

Purpose of the Study:

  • To review the role of germline genetic variation in chemotherapeutic toxicity and response.
  • To discuss the application of genome-wide association studies and lymphoblastoid cell lines (LCLs) in pharmacogenomic research.
  • To highlight recent discoveries of genetic variants impacting chemotherapy outcomes and explore future directions.

Main Methods:

  • Review of existing literature on pharmacogenomics in cancer treatment.
  • Analysis of genome-wide association studies (GWAS).
  • Utilizing lymphoblastoid cell lines (LCLs) for pharmacogenomic investigations.

Main Results:

  • Identification of pharmacogenetic markers predicting chemotherapy response and toxicity.
  • Examples of genetic variants associated with chemotherapy outcomes in patient cohorts and LCLs.
  • Advances in genotyping and sequencing technologies facilitate pharmacogenetic discoveries.

Conclusions:

  • Germline genetic variation significantly impacts chemotherapeutic toxicity and response.
  • Genome-wide association studies and LCLs are valuable tools in pharmacogenomic discovery.
  • Clinical implementation of pharmacogenetic markers remains a challenge, requiring further research and development.
Keywords:
International HapMap ProjectPharmacogenomicschemotherapeuticsclinical translationgenome-wide association studies

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...